These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11382124)

  • 1. [Case report on therapy with granulocyte stimulating factor in diabetic foot].
    Kreyden OP; Hafner J; Burg G; Nestle FO
    Hautarzt; 2001 Apr; 52(4):327-30. PubMed ID: 11382124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection.
    Yönem A; Cakir B; Güler S; Azal O O; Corakçi A
    Diabetes Obes Metab; 2001 Oct; 3(5):332-7. PubMed ID: 11703423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection.
    Gough A; Clapperton M; Rolando N; Foster AV; Philpott-Howard J; Edmonds ME
    Lancet; 1997 Sep; 350(9081):855-9. PubMed ID: 9310604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission.
    Weiss M; Voglic S; Harms-Schirra B; Lorenz I; Lasch B; Dumon K; Gross-Weege W; Schneider EM
    Intensive Care Med; 2003 Jun; 29(6):904-914. PubMed ID: 12682721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers.
    Kästenbauer T; Hörnlein B; Sokol G; Irsigler K
    Diabetologia; 2003 Jan; 46(1):27-30. PubMed ID: 12637979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections.
    Cruciani M; Lipsky BA; Mengoli C; de Lalla F
    Cochrane Database Syst Rev; 2009 Jul; (3):CD006810. PubMed ID: 19588405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced neutrophil functions by recombinant human granulocyte colony-stimulating factor in diabetic patients with foot infections in vitro.
    Peck KR; Son DW; Song JH; Kim S; Oh MD; Choe KW
    J Korean Med Sci; 2001 Feb; 16(1):39-44. PubMed ID: 11289399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. The Filgrastim Study Group.
    Heard SO; Fink MP; Gamelli RL; Solomkin JS; Joshi M; Trask AL; Fabian TC; Hudson LD; Gerold KB; Logan ED
    Crit Care Med; 1998 Apr; 26(4):748-54. PubMed ID: 9559614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of recombinant human granulocyte colony-stimulating factor on neutrophil function in vitro and in vivo following chemotherapy and autologous bone marrow transplantation.
    Humphreys JM; Rugman FP; Davies JM; Mimnagh P; Hart CA; Edwards SW
    J Clin Lab Immunol; 1991 Feb; 34(2):55-61. PubMed ID: 1725883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo effects of granulocyte colony-stimulating factor on neutrophils in glycogen storage disease type 1B: granulocyte colony-stimulating factor therapy corrects the neutropenia and the defects in respiratory burst activity and Ca2+ mobilization.
    McCawley LJ; Korchak HM; Douglas SD; Campbell DE; Thornton PS; Stanley CA; Baker L; Kilpatrick L
    Pediatr Res; 1994 Jan; 35(1):84-90. PubMed ID: 7510873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive granulocyte colony-stimulating factor therapy for diabetic foot infections.
    Reed KS; Pai MP
    Ann Pharmacother; 2004 Dec; 38(12):2150-3. PubMed ID: 15494384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of G-CSF (Neupogen) in multimodal treatment in radiotherapy].
    Bartzsch O; Riepl M; Busch M; Michael G; Allgäuer M; Voss AC; Sauer R; Dühmke E; Gademann G; Molls M
    Strahlenther Onkol; 1998 Nov; 174(11):551-5. PubMed ID: 9830435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.
    Kennedy MJ; Davis J; Passos-Coelho J; Noga SJ; Huelskamp AM; Ohly K; Davidson NE
    Cancer Res; 1993 Nov; 53(22):5424-8. PubMed ID: 7693341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC
    Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Actin polymerization in neutrophils from donors of peripheral blood stem cells: divergent effects of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factor.
    Carulli G; Mattii L; Azzarà A; Brizzi S; Galimberti S; Zucca A; Benedetti E; Petrini M
    Am J Hematol; 2006 May; 81(5):318-23. PubMed ID: 16628714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
    Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
    Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clozapine rechallenge in resistant schizophrenia disorder affecting "super sensitive" patients, after neutropenia under clozapine: a case report].
    Huguet G; Lillo-Le Louet A; Darnige L; Loo H; Krebs MO
    Encephale; 2013 May; 39 Suppl 1():S42-8. PubMed ID: 23557674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers.
    Lubenau H; Sveikata A; Gumbrevicius G; Macijauskiene J; Fokas V; Kazlauskas S; Janulionis V
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):275-82. PubMed ID: 19356394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and beta2 integrin expression. Results of a randomized controlled trial.
    Drossou-Agakidou V; Kanakoudi-Tsakalidou F; Sarafidis K; Taparkou A; Tzimouli V; Tsandali H; Kremenopoulos G
    Eur J Pediatr; 1998 Jul; 157(7):583-8. PubMed ID: 9686822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.